CL2023000146A1 - Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas - Google Patents

Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas

Info

Publication number
CL2023000146A1
CL2023000146A1 CL2023000146A CL2023000146A CL2023000146A1 CL 2023000146 A1 CL2023000146 A1 CL 2023000146A1 CL 2023000146 A CL2023000146 A CL 2023000146A CL 2023000146 A CL2023000146 A CL 2023000146A CL 2023000146 A1 CL2023000146 A1 CL 2023000146A1
Authority
CL
Chile
Prior art keywords
viscosity
combinations
highly concentrated
concentrated protein
protein formulations
Prior art date
Application number
CL2023000146A
Other languages
English (en)
Inventor
Rosenkranz Tobias
Braun Stefan
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2023000146A1 publication Critical patent/CL2023000146A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con composiciones y formulaciones líquidas que comprenden una proteína que tiene una viscosidad reducida y/o una estabilidad aumentada. Además, la invención se relaciona con métodos para reducir la viscosidad y/o aumentar la estabilidad de una solución de proteínas.
CL2023000146A 2020-07-13 2023-01-13 Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas CL2023000146A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185558 2020-07-13
EP20204464 2020-10-28

Publications (1)

Publication Number Publication Date
CL2023000146A1 true CL2023000146A1 (es) 2023-09-01

Family

ID=76891081

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000146A CL2023000146A1 (es) 2020-07-13 2023-01-13 Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas

Country Status (13)

Country Link
US (1) US20230279146A1 (es)
EP (1) EP4178531A1 (es)
JP (1) JP2023533704A (es)
KR (1) KR20230038752A (es)
CN (1) CN115803011A (es)
AU (1) AU2021308997A1 (es)
BR (1) BR112022026670A2 (es)
CA (1) CA3187322A1 (es)
CL (1) CL2023000146A1 (es)
CO (1) CO2023000239A2 (es)
IL (1) IL299671A (es)
MX (1) MX2023000557A (es)
WO (1) WO2022013171A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230167968A (ko) * 2022-06-03 2023-12-12 주식회사 녹십자홀딩스 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
SI1324776T2 (en) 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP3365021A4 (en) 2015-10-23 2019-06-05 Reform Biologics, LLC AUXILIARY COMPOUNDS FOR BIOPOLYMER FORMULATIONS
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
US20200352857A1 (en) * 2017-04-28 2020-11-12 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
EP3624846B1 (en) * 2017-05-16 2024-08-07 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan
BR112020021094A2 (pt) 2018-04-16 2021-02-23 Merck Patent Gmbh redução da viscosidade de formulações de proteínas altamente concentradas

Also Published As

Publication number Publication date
AU2021308997A1 (en) 2023-02-02
BR112022026670A2 (pt) 2023-01-24
KR20230038752A (ko) 2023-03-21
WO2022013171A1 (en) 2022-01-20
JP2023533704A (ja) 2023-08-04
IL299671A (en) 2023-03-01
MX2023000557A (es) 2023-02-13
CA3187322A1 (en) 2022-01-20
CN115803011A (zh) 2023-03-14
EP4178531A1 (en) 2023-05-17
CO2023000239A2 (es) 2023-02-06
US20230279146A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
NI201800139A (es) Formulación farmacéutica líquida estable
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2023000146A1 (es) Excipientes reductores de la viscosidad y combinaciones de los mismos para formulaciones proteicas altamente concentradas
CL2021001956A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables. (divisional solicitud 202002624)
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
NI202000085A (es) Moduladores de la expresión de apol1
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
AR105894A1 (es) Composición para aplicación tópica que comprende dimetil isosorbida, un poliol, y un antioxidante fenólico o polifenólico
CO2021014260A2 (es) Formas sólidas de un inhibidor de glyt1
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
BR112018077510A2 (pt) variantes de lipase e composições que compreendem tensoativo e variante de lipase
CL2021003328A1 (es) Composiciones que comprenden iga secretora y probióticos.
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112021000279A8 (pt) formulações de redução de tumor e métodos de uso das mesmas
BR112017020324A2 (pt) composições de peróxido inorgânico coloridas e métodos de quebra de fluidos de fraturamento hidráulico